Alpha 2.0
Login Register
» Authors » Devchand Paul

Devchand Paul

Explore the profile of Devchand Paul including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 856
Followers 0
Related Specialties
Oncology
Radiology
General Medicine
Top 10 Co-Authors
Joanne L Blum
Lina Asmar
Scot Sedlacek
Joyce A OShaughnessy
Nicholas J Robert
Svetislava J Vukelja
Svetislava Vukelja
Frankie Ann Holmes
Adam Brufsky
Adam M Brufsky
Published In
Clin Breast Cancer
Breast Cancer Res Treat
J Clin Oncol
Clin Cancer Res
Int J Radiat Oncol Biol Phys
Affiliations
Soon will be listed here.
Recent Articles
11.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study
Jones S, Collea R, Paul D, Sedlacek S, Favret A, Gore Jr I, et al.
Lancet Oncol . 2013 Sep; 14(11):1121-1128. PMID: 24007746
Background: Previous results suggest that docetaxel plus cyclophosphamide improves disease-free survival (DFS) and overall survival compared with doxorubicin plus cyclophosphamide in early stage breast cancer. We assessed the addition of...
12.
Effect of dietary patterns differing in carbohydrate and fat content on blood lipid and glucose profiles based on weight-loss success of breast-cancer survivors
Thompson H, Sedlacek S, Paul D, Wolfe P, McGinley J, Playdon M, et al.
Breast Cancer Res . 2012 Jan; 14(1):R1. PMID: 22225711
Introduction: Healthy body weight is an important factor for prevention of breast cancer recurrence. Yet, weight loss and weight gain are not currently included in clinical-practice guidelines for posttreatment of...
13.
Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer
Pippen J, Paul D, Vukelja S, Clawson A, Iglesias J
Breast Cancer Res Treat . 2011 Oct; 130(3):825-31. PMID: 21976055
Unlabelled: Every-2-week (dose-dense) adjuvant doxorubicin (A) plus cyclophosphamide (C) followed by cremophor-formulated paclitaxel (cf-P) was efficacious in metastatic breast cancer (BC). Albumin-bound paclitaxel (ab-P) was safe and more effective than...
14.
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer
Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, et al.
Clin Breast Cancer . 2011 Jul; 11(4):211-20. PMID: 21723792
Background: The addition of bevacizumab to paclitaxel improved progression-free survival (PFS) of patients with metastatic breast cancer (MBC). We examined the efficacy and safety of adding gemcitabine to paclitaxel/bevacizumab (PB)....
15.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial
Robert N, Saleh M, Paul D, Generali D, Gressot L, Copur M, et al.
Clin Breast Cancer . 2011 May; 11(2):82-92. PMID: 21569994
Introduction: A multicenter, open-label phase III study was conducted to test whether sunitinib plus paclitaxel prolongs progression-free survival (PFS) compared with bevacizumab plus paclitaxel as first-line treatment for patients with...
16.
Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol
Leonard C, Tallhamer M, Johnson T, Hunter K, Howell K, Kercher J, et al.
Int J Radiat Oncol Biol Phys . 2009 May; 76(2):528-34. PMID: 19467799
Purpose: To explore the feasibility of fiducial markers for the use of image-guided radiotherapy (IGRT) in an accelerated partial breast intensity modulated radiotherapy protocol. Methods And Materials: Nineteen patients consented...
17.
Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
Ellis G, Bone H, Chlebowski R, Paul D, Spadafora S, Fan M, et al.
Breast Cancer Res Treat . 2009 Mar; 118(1):81-7. PMID: 19308727
Denosumab increased lumbar spine bone mineral density (BMD) versus placebo in a 2-year, randomized, placebo-controlled, phase 3 study of patients with hormone-receptor-positive, non-metastatic breast cancer and low bone mass who...
18.
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H, et al.
Clin Cancer Res . 2009 Feb; 15(4):1452-9. PMID: 19228746
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited...
19.
The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer
Osborne C, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, et al.
Breast Cancer Res Treat . 2009 Jan; 116(3):521-7. PMID: 19139988
Tamoxifen significantly reduces the risk of developing breast cancer in women at increased-risk. The usefulness of tamoxifen has been limited by its side effect profile, especially its propensity to worsen...
20.
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer
Jones S, Stokoe C, Sborov M, Braun M, Ethirajan S, Kutteh L, et al.
Clin Breast Cancer . 2008 Dec; 8(6):527-32. PMID: 19073509
Background: Adjuvant therapy with aromatase inhibitors is associated with increased bone loss in postmenopausal women with breast cancer. We assessed changes in bone mineral density (BMD) from baseline to 24...